ImmunityBio develops targeted immunotherapies that activate natural killer and T cells to enhance the immune response against cancer, specifically addressing the limitations of traditional therapies that weaken the immune system. Their first-in-class treatment, ANKTIVA, has shown a complete response rate of 71% in clinical trials for non-muscle invasive bladder cancer, demonstrating significant potential for durable patient outcomes.
Funding
$100M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancer therapies can severely weaken a patient's immune system, hindering the body's natural ability to fight the disease. Traditional approaches like chemotherapy and radiation can compromise the immune system, reducing its effectiveness in combating tumors and infections. This creates a need for therapies that strengthen, rather than weaken, the immune response.
Solution
ImmunityBio develops targeted immunotherapies designed to activate natural killer (NK) cells and T cells, enhancing the body's immune response to fight cancer and infectious diseases. Their approach aims to strengthen the immune system, enabling it to target and eliminate cancerous or infected cells while establishing immunological memory for long-term protection. The company's investigational products are tailored to each patient's needs, employing a "triangle offense" designed to deliver durable, complete responses. ImmunityBio's platforms harness both innate and adaptive functions of the immune system, activating NK cells, T cells, and macrophages, and establishing immune memory by dendritic cells.
Target Audience
The primary target audience includes patients with advanced cancers and infectious diseases, clinical trial investigators, and research scientists seeking tools to develop functional killing assays.
Features
- NK-92® cell line provides a versatile bioanalytical testing tool for functional killing assays
- ANKTIVA® (N-803), an IL-15 superagonist fusion protein, designed to induce expansion of native NK and CD8+ T-cells without concurrent stimulation of T-regulatory cells
- Next-generation adenovirus-vectored anti-cancer vaccines
- Neoepitope prediction pipeline to identify tumor-associated neoepitope peptides for personalized vaccines
- QUILT (QUantum Integrative Lifelong Trial) clinical trial program
- Cancer BioShield™ platform for treating solid tumor lymphopenia
- Recombinant BCG (rBCG) for bladder cancer